Author:
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Neuber H, 2008. Leishmaniasis. J Dtsch Dermatol Ges 6: 754–765.
-
2.
Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA, 2009. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev CD004834.
-
3.
Alvar J, Yactayo S, Bern C, 2006. Leishmaniasis and poverty. Trends Parasitol 22: 552–557.
-
4.
Bailey MS, Lockwood DN, 2007. Cutaneous leishmaniasis. Clin Dermatol 25: 203–211.
-
5.
Soto J, Soto P, 2006. Current situation and future of antileishmanial therapy in Colombia. Biomedica (Bogota) 26 (Suppl 1): 194–206.
-
6.
Kedzierski L, Sakthianandeswaren A, Curtis JM, Andrews PC, Junk PC, Kedzierska K, 2009. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem 16: 599–614.
-
7.
Murray HW, Berman JD, Davies CR, Saravia NG, 2005. Advances in leishmaniasis. Lancet 366: 1561–1577.
-
8.
Ouellette M, Drummelsmith J, Papadopoulou B, 2004. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat 7: 257–266.
-
9.
Palumbo E, 2009. Current treatment for cutaneous leishmaniasis: a review. Am J Ther 16: 178–182.
-
10.
Arevalo I, Tulliano G, Quispe A, Spaeth G, Matlashewski G, Llanos-Cuentas A, Pollack H, 2007. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 44: 1549–1554.
-
11.
Berman JD, 1996. Treatment of New World cutaneous and mucosal leishmaniases. Clin Dermatol 14: 519–522.
-
12.
Sampaio RN, de Paula CD, Sampaio JH, Furtado Rde S, Leal PP, Rosa TT, Rodrigues ME, Veiga JP, 1997. The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg Sb V/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis. Rev Soc Bras Med Trop 30: 457–463.
-
13.
Santos JB, de Jesus AR, Machado PR, Magalhaes A, Salgado K, Carvalho EM, Almeida RP, 2004. Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous Leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study. J Infect Dis 190: 1793–1796.
-
14.
Seaton RA, Morrison J, Man I, Watson J, Nathwani D, 1999. Out-patient parenteral antimicrobial therapy—a viable option for the management of cutaneous leishmaniasis. QJM 92: 659–667.
-
15.
Osorio LE, Palacios R, Chica ME, Ochoa MT, 1998. Treatment of cutaneous leishmaniasis in Colombia with dapsone. Lancet 351: 498–499.
-
16.
Momeni AZ, Aminjavaheri M, Omidghaemi MR, 2003. Treatment of cutaneous leishmaniasis with ketoconazole cream. J Dermatolog Treat 14: 26–29.
-
17.
Singh S, Singh R, Sundar S, 1995. Failure of ketoconazole treatment in cutaneous leishmaniasis. Int J Dermatol 34: 120–121.
-
18.
Hendrickx EP, Agudelo SP, Munoz DL, Puerta JA, Velez Bernal ID, 1998. Lack of efficacy of mefloquine in the treatment of New World cutaneous leishmaniasis in Colombia. Am J Trop Med Hyg 59: 889–892.
-
19.
Velez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, Berman J, 1997. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann Intern Med 126: 232–236.
-
20.
Bari AU, Rahman SB, 2003. A therapeutic update on cutaneous leishmaniasis. J Coll Physicians Surg Pak 13: 471–476.
-
21.
Croft SL, Engel J, 2006. Miltefosine–discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg 100 (Suppl 1): S4–S8.
-
22.
Croft SL, Snowdon D, Yardley V, 1996. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 38: 1041–1047.
-
23.
Escobar P, Matu S, Marques C, Croft SL, 2002. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop 81: 151–157.
-
24.
Nakayama H, Loiseau PM, Bories C, Torres de Ortiz S, Schinini A, Serna E, Rojas de Arias A, Fakhfakh MA, Franck X, Figadere B, Hocquemiller R, Fournet A, 2005. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents Chemother 49: 4950–4956.
-
25.
Yardley V, Croft SL, De Doncker S, Dujardin JC, Koirala S, Rijal S, Miranda C, Llanos-Cuentas A, Chappuis F, 2005. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg 73: 272–275.
-
26.
Escobar P, Yardley V, Croft SL, 2001. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob Agents Chemother 45: 1872–1875.
-
27.
Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739–1746.
-
28.
Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, Hilgard P, Murray HW, 1998. Trial of oral miltefosine for visceral leishmaniasis. Lancet 352: 1821–1823.
-
29.
Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H, 2004. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38: 1266–1272.
-
30.
Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J, 2001. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 33: E57–E61.
-
31.
Velez ID, 1996. Diagnóstico. Antioquia Ud, ed. Leishmaniosis Manual de Procedimientos para el Diagnóstico de la Leishmaniosis Cutánea Americana Medellín Colombia: University of Antioquia, 13–18.
-
32.
Singh S, Dey A, Sivakumar R, 2005. Applications of molecular methods for Leishmania control. Expert Rev Mol Diagn 5: 251–265.
-
33.
Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P, 2003. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176–181.
-
34.
Velez ID, Hendrickx E, Robledo SM, del Pilar Agudelo S, 2001. Gender and cutaneous leishmaniasis in Colombia. Cad Saude Publica 17: 171–180.
-
35.
Soto J, Rea J, Balderrama M, Toledo J, Soto P, Valda L, Berman JD, 2008. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 78: 210–211.
-
36.
Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Ardiles J, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J, 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44: 350–356.
-
37.
Gonzalez LM, Velez ID, 2006. Miltefosine for disseminated cutaneous leishmaniasis. Biomedica (Bogota) 26 (Suppl 1): 13–16.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 81 | 81 | 14 |
| Full Text Views | 445 | 180 | 0 |
| PDF Downloads | 198 | 93 | 0 |
Efficacy of Miltefosine for the Treatment of American Cutaneous Leishmaniasis
Iván Vélez
Iván Vélez
Programa de Estudio y Control de Enfermedades Tropicales, PECET, Universidad de Antioquia, Medellín, Colombia; Dirección de Sanidad, DISAN, Ejército de Colombia; Grupo de epidemiología, Universidad de Antioquia, Medellín, Colombia
Search for other papers by Iván Vélez in
Current site
Google Scholar
PubMed
Search for other papers by Iván Vélez in
Current site
Google Scholar
PubMed
Liliana López
Liliana López
Programa de Estudio y Control de Enfermedades Tropicales, PECET, Universidad de Antioquia, Medellín, Colombia; Dirección de Sanidad, DISAN, Ejército de Colombia; Grupo de epidemiología, Universidad de Antioquia, Medellín, Colombia
Search for other papers by Liliana López in
Current site
Google Scholar
PubMed
Search for other papers by Liliana López in
Current site
Google Scholar
PubMed
Ximena Sánchez
Ximena Sánchez
Programa de Estudio y Control de Enfermedades Tropicales, PECET, Universidad de Antioquia, Medellín, Colombia; Dirección de Sanidad, DISAN, Ejército de Colombia; Grupo de epidemiología, Universidad de Antioquia, Medellín, Colombia
Search for other papers by Ximena Sánchez in
Current site
Google Scholar
PubMed
Search for other papers by Ximena Sánchez in
Current site
Google Scholar
PubMed
Laureano Mestra
Laureano Mestra
Programa de Estudio y Control de Enfermedades Tropicales, PECET, Universidad de Antioquia, Medellín, Colombia; Dirección de Sanidad, DISAN, Ejército de Colombia; Grupo de epidemiología, Universidad de Antioquia, Medellín, Colombia
Search for other papers by Laureano Mestra in
Current site
Google Scholar
PubMed
Search for other papers by Laureano Mestra in
Current site
Google Scholar
PubMed
Carlos Rojas
Carlos Rojas
Programa de Estudio y Control de Enfermedades Tropicales, PECET, Universidad de Antioquia, Medellín, Colombia; Dirección de Sanidad, DISAN, Ejército de Colombia; Grupo de epidemiología, Universidad de Antioquia, Medellín, Colombia
Search for other papers by Carlos Rojas in
Current site
Google Scholar
PubMed
Search for other papers by Carlos Rojas in
Current site
Google Scholar
PubMed
Erwin Rodríguez
Erwin Rodríguez
Programa de Estudio y Control de Enfermedades Tropicales, PECET, Universidad de Antioquia, Medellín, Colombia; Dirección de Sanidad, DISAN, Ejército de Colombia; Grupo de epidemiología, Universidad de Antioquia, Medellín, Colombia
Search for other papers by Erwin Rodríguez in
Current site
Google Scholar
PubMed
Search for other papers by Erwin Rodríguez in
Current site
Google Scholar
PubMed
Miltefosine is an oral agent used for cutaneous leishmaniasis treatment. An open-label, randomized, phase III clinical trial was carried out in the Colombian army population. Miltefosine, 50 mg capsule was taken orally three times per day for 28 days (N = 145) or meglumine antimoniate, 20 mg/kg body weight per day for 20 days by intramuscular injection (N = 143). The efficacy of miltefosine by protocol was 69.8% (85/122 patients) and 58.6% (85/145 patients) by intention to treat. For meglumine antimoniate, the efficacy by protocol was 85.1% (103/121 patients) and 72% (103/143 patients) by intention to treat. No association was found between drug efficacy and L. (V.) braziliensis or L. (V.) panamensis species of Leishmania responsible for infection. Adverse gastrointestinal events were associated with the use of miltefosine, the meglumine antimoniate treatment was associated with adverse effects on the skeletal musculature, fever, cephalea, and higher toxicity in kidney, liver, pancreas, and hematological system.
Author Notes
Financial support: The study was financed by the Ministerio de la Protección Social de la República de Colombia, which did not participate in the design, execution and/or reporting of the study.
Authors' addresses: Iván Vélez, Liliana López, and Laureano Mestra, Programa de Estudio y Control de Enfermedades Tropicales, PECET, Universidad de Antioquia, Medellín, Colombia, E-mails: idvelez@pecet-colombia.org, lililop14@yahoo.com, and laureanomestra@gmail.com. Ximena Sánchez and Erwin Rodríguez, Dirección de Sanidad, DISAN, Ejército de Colombia, E-mails: ximsan@hotmail.com and erroga@yahoo.com. Carlos Rojas, Grupo de Epidemiología, Facultad Nacional de Salud Pública, Universidad de Antioquia, E-mail: crojas@guajiros.udea.edu.co.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Neuber H, 2008. Leishmaniasis. J Dtsch Dermatol Ges 6: 754–765.
-
2.
Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA, 2009. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev CD004834.
-
3.
Alvar J, Yactayo S, Bern C, 2006. Leishmaniasis and poverty. Trends Parasitol 22: 552–557.
-
4.
Bailey MS, Lockwood DN, 2007. Cutaneous leishmaniasis. Clin Dermatol 25: 203–211.
-
5.
Soto J, Soto P, 2006. Current situation and future of antileishmanial therapy in Colombia. Biomedica (Bogota) 26 (Suppl 1): 194–206.
-
6.
Kedzierski L, Sakthianandeswaren A, Curtis JM, Andrews PC, Junk PC, Kedzierska K, 2009. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem 16: 599–614.
-
7.
Murray HW, Berman JD, Davies CR, Saravia NG, 2005. Advances in leishmaniasis. Lancet 366: 1561–1577.
-
8.
Ouellette M, Drummelsmith J, Papadopoulou B, 2004. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat 7: 257–266.
-
9.
Palumbo E, 2009. Current treatment for cutaneous leishmaniasis: a review. Am J Ther 16: 178–182.
-
10.
Arevalo I, Tulliano G, Quispe A, Spaeth G, Matlashewski G, Llanos-Cuentas A, Pollack H, 2007. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 44: 1549–1554.
-
11.
Berman JD, 1996. Treatment of New World cutaneous and mucosal leishmaniases. Clin Dermatol 14: 519–522.
-
12.
Sampaio RN, de Paula CD, Sampaio JH, Furtado Rde S, Leal PP, Rosa TT, Rodrigues ME, Veiga JP, 1997. The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg Sb V/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis. Rev Soc Bras Med Trop 30: 457–463.
-
13.
Santos JB, de Jesus AR, Machado PR, Magalhaes A, Salgado K, Carvalho EM, Almeida RP, 2004. Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous Leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study. J Infect Dis 190: 1793–1796.
-
14.
Seaton RA, Morrison J, Man I, Watson J, Nathwani D, 1999. Out-patient parenteral antimicrobial therapy—a viable option for the management of cutaneous leishmaniasis. QJM 92: 659–667.
-
15.
Osorio LE, Palacios R, Chica ME, Ochoa MT, 1998. Treatment of cutaneous leishmaniasis in Colombia with dapsone. Lancet 351: 498–499.
-
16.
Momeni AZ, Aminjavaheri M, Omidghaemi MR, 2003. Treatment of cutaneous leishmaniasis with ketoconazole cream. J Dermatolog Treat 14: 26–29.
-
17.
Singh S, Singh R, Sundar S, 1995. Failure of ketoconazole treatment in cutaneous leishmaniasis. Int J Dermatol 34: 120–121.
-
18.
Hendrickx EP, Agudelo SP, Munoz DL, Puerta JA, Velez Bernal ID, 1998. Lack of efficacy of mefloquine in the treatment of New World cutaneous leishmaniasis in Colombia. Am J Trop Med Hyg 59: 889–892.
-
19.
Velez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, Berman J, 1997. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann Intern Med 126: 232–236.
-
20.
Bari AU, Rahman SB, 2003. A therapeutic update on cutaneous leishmaniasis. J Coll Physicians Surg Pak 13: 471–476.
-
21.
Croft SL, Engel J, 2006. Miltefosine–discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg 100 (Suppl 1): S4–S8.
-
22.
Croft SL, Snowdon D, Yardley V, 1996. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 38: 1041–1047.
-
23.
Escobar P, Matu S, Marques C, Croft SL, 2002. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop 81: 151–157.
-
24.
Nakayama H, Loiseau PM, Bories C, Torres de Ortiz S, Schinini A, Serna E, Rojas de Arias A, Fakhfakh MA, Franck X, Figadere B, Hocquemiller R, Fournet A, 2005. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents Chemother 49: 4950–4956.
-
25.
Yardley V, Croft SL, De Doncker S, Dujardin JC, Koirala S, Rijal S, Miranda C, Llanos-Cuentas A, Chappuis F, 2005. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg 73: 272–275.
-
26.
Escobar P, Yardley V, Croft SL, 2001. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob Agents Chemother 45: 1872–1875.
-
27.
Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739–1746.
-
28.
Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, Hilgard P, Murray HW, 1998. Trial of oral miltefosine for visceral leishmaniasis. Lancet 352: 1821–1823.
-
29.
Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Diaz A, Luz M, Gutierrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H, 2004. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38: 1266–1272.
-
30.
Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J, 2001. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 33: E57–E61.
-
31.
Velez ID, 1996. Diagnóstico. Antioquia Ud, ed. Leishmaniosis Manual de Procedimientos para el Diagnóstico de la Leishmaniosis Cutánea Americana Medellín Colombia: University of Antioquia, 13–18.
-
32.
Singh S, Dey A, Sivakumar R, 2005. Applications of molecular methods for Leishmania control. Expert Rev Mol Diagn 5: 251–265.
-
33.
Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P, 2003. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176–181.
-
34.
Velez ID, Hendrickx E, Robledo SM, del Pilar Agudelo S, 2001. Gender and cutaneous leishmaniasis in Colombia. Cad Saude Publica 17: 171–180.
-
35.
Soto J, Rea J, Balderrama M, Toledo J, Soto P, Valda L, Berman JD, 2008. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 78: 210–211.
-
36.
Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Ardiles J, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J, 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44: 350–356.
-
37.
Gonzalez LM, Velez ID, 2006. Miltefosine for disseminated cutaneous leishmaniasis. Biomedica (Bogota) 26 (Suppl 1): 13–16.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 81 | 81 | 14 |
| Full Text Views | 445 | 180 | 0 |
| PDF Downloads | 198 | 93 | 0 |